Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum phase 3 trial in diffuse cutaneous systemic sclerosis
NL-OMON48900Phase 3Active, not recruiting
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenabasum in systemic sclerosis (SSc) (4 arms), sponsored by Corbus Pharmaceuticals Holdings, Inc. Primary endpoints: ACR CRISS score at Week 52 and Treatment-emergent adverse events. Started Sep 2018; status: active, not recruiting.
02
Drugs
lenabasum
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON48900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48900.